Abstract:Introduction: Autoimmune nodopathy (AN) is a new entity in the field of peripheral neuropathies and is defined by the presence of auto-antibodies against structures of the node of Ranvier combined with specific clinico-pathophysiological features and therapy response in affected patients. The target-specific antibodies do not only serve as diagnostic biomarkers but also for treatment evaluation during follow-up. Case report: We report a 66-year-old female patient with various autoimmune diseases, including a history of membranous glomerulonephritis which presented with acute-onset, sensorimotor tetraparesis, cranial nerve involvement, and mild respiratory insufficiency. Under the suspicion of Guillain-Barré syndrome, she received intravenous immunoglobulins (IVIg) and achieved remission. At 8 months later, she relapsed with now a poor response to IVIg and developed additional features such as severe sensory ataxia, tremor, and neuropathic pain. Anti-contactin-1 IgG2 antibodies were detected, and the diagnosis was reverted to AN. Plasma exchange and rituximab treatment led to a serological remission and corresponding significant clinical improvement, and the therapy was paused. At 2 years after symptom onset, her condition worsened again with sensorimotor symptoms and severe neuropathic pain despite seronegativity for contactin-1. However, serum binding assays to teased nerve fiber staining showed recurring antibody reactivity against paranodal structures. Caspr-1 was identified as a new target antigen via cell-based assay, and high-titer antibodies of the IgG4 subclass were confirmed via ELISA. Hence, a new cycle of plasma exchange and regular rituximab treatment was initiated, with subsequent clinical improvement and serological remission. The serum neurofilament light chain (sNFL) levels were assessed retrospectively and rose and fell together with the antibody titer. Discussion: This case demonstrates that autoimmunity to (para)nodal structures can reoccur especially in patients prone to autoimmune disorders and can switch its target antigen and subclass in the course of disease. The presence of auto-antibodies against different targets at the node of Ranvier has direct implications for therapeutic management. We suggest a close follow-up of patients with AN after successful therapy. In case of deterioration despite seronegativity, non-specific tests such as teased fiber assays and repeated screening for different target antigens should be considered.

Favorable long-term outcomes of autoimmune nodopathy with mycophenolate mofetil

Anti-NF155/NF186 IgG4 Antibody Positive Autoimmune Nodopathy

Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies

Clinical Features of Autoimmune Nodopathy With Anti-Neurofascin-155 Antibodies in South Koreans

Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins

Case report: target antigen and subclass switch in a patient with autoimmune nodopathy

Characteristics of anti-contactin1 antibody positive autoimmune nodopathies combined with membranous nephropathy

Case report: Immunoadsorption therapy for anti-caspr1 antibody-associated nodopathy

Effectiveness and Safety of Rituximab in Autoimmune Nodopathy: a Single-Center Cohort Study

Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies

An immuno-DOT diagnostic assay for autoimmune nodopathy

Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

Characteristics of Anti-Contactin1 Antibody-Associated Autoimmune Nodopathies With Concomitant Membranous Nephropathy

Clinical Profile of Autoimmune Nodopathy with Anti‐neurofascin 186 Antibody

Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody

Long term follow-up in anti-contactin-1 autoimmune nodopathy

Autoimmune nodopathy with anti-contactin 1 antibody characterized by cerebellar dysarthria: a case report and literature review

Efficacy and Safety of Mycophenolate Mofetil in Patients with IgA Nephropathy: an Update Meta-Analysis

Seronegative necrotizing autoimmune myopathy with favorable response to intravenous immunoglobulin

Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.